Paula Casajust

RWD24 A Target Trial Emulation Design to Seek EMA Approval for a Reformulated Drug With a Non-Inferiority, Pivotal, Retrospective Study: A Success Story

Magda Bosch de Basea Gómez, N. Valveny, Paula Casajust, Millie Samaniego et autres

es (code pays fourni par la source)

Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen et autres

Objective: To evaluate the effectiveness of empagliflozin in reducing all‐cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end‐stage renal disease (ESRD) in routine clinical practice in the Nordic countries of the Empagliflozin Comparative Effectiveness …

no, se, dk, us, gb, fi, br, de, Égypte, cn (code pays fourni par la source)

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

Dorte Vistisen, Bendix Carstensen, Patorno E Elisabetta, Stefanie Lanzinger et autres

BACKGROUND: Studies that have reported lower risk for cardiovascular outcomes in users of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD). This study compared risk of cardiovascular events in patients within routine …

dk, us, de, tw, jp, kr, il, es, no, se, fi, fr, gb (code pays fourni par la source)

Lääkevalinnalla on merkitystä tyypin 2 diabeteksessa

Leo Niskanen, Emilie Toresson-Grip, Joel Gunnarsson, Paula Casajust et autres

Lähtökohdat : Vertailimme empagliflotsiinin ja dipeptidyylipeptidaasi-4:n (DPP-4) estäjien vaikuttavuutta ja terveydenhuollon resurssien käyttöä Suomessa. Työ tehtiin osana EU:n ja Aasian Emprise-tutkimusta (EUPAS27606, NCT03817463). Menetelmät : Ei-interventionaalinen, retrospektiivinen kohorttitutkimus käytti suomalaisia rekisteriaineistoja. Aikuiset, jotka aloittivat tyypin 2 diabetekseensa lääkehoidon empagliflotsiinilla tai DPP-4:n estäjillä …

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study

Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson, Paula Casajust et autres

Abstract Aims To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463). Materials and Methods A non‐interventional, cohort study using retrospectively collected data from …

se, es, de (code pays fourni par la source)

Author response for "Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: real world evidence from the Nordic EMPRISE study"

Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson, Paula Casajust et autres

Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design

Lana Yin Hui Lai, Faaizah Arshad, Carlos Morgado Areia, Thamir M. Alshammari et autres

Post-marketing vaccine safety surveillance aims to detect adverse events following immunization in a population. Whether certain methods of surveillance are more precise and unbiased in generating safety signals is unclear. Here, we synthesized information from existing literature to provide an overview of …

gb, us, sa, ps, Égypte, se, au (code pays fourni par la source)

Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

Kristin Kostka, Talita Duarte‐Salles, Albert Prats‐Uribe, Anthony G. Sena et autres

Purpose: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) …

us, es, gb, nl, sa, se, kr, au, ca, ps, cn (code pays fourni par la source)

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Daniel R. Morales, Anna Ostropolets, Lana Yin Hui Lai, Anthony G. Sena et autres

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 …

gb, dk, us, nl, sa, ps, kr, ca, se, es, cn (code pays fourni par la source)

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Daniel R. Morales, Anna Ostropolets, Lana Yin Hui Lai, Anthony G. Sena et autres

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma. Methods: We included nine databases contributing data from January to June …

gb, dk, ps, ch, kr, au, se, es, cn, ca, us, jp (code pays fourni par la source)

Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis

Xintong Li, Lana Yin Hui Lai, Anna Ostropolets, Faaizah Arshad et autres

Using real-world data and past vaccination data, we conducted a large-scale experiment to quantify bias, precision and timeliness of different study designs to estimate historical background (expected) compared to post-vaccination (observed) rates of safety events for several vaccines. We used negative (not …

gb, us, sa, es, ca, au (code pays fourni par la source)

Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain

Elena Roel, Andrea Pistillo, Martina Recalde, Anthony G. Sena et autres

Abstract Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We …

es, nl, us, gb, ps, sa, Égypte, cn, kr, au, ca, dk, se, fr, it (code pays fourni par la source)